OSTX Stock Catalyst: OS Therapies Inks Agreements for Commercial Manufacture of Lead Cancer Drug

Feb 13, 2025 · 5:31pm ET

Initiates commercial-ready manufacturing of OST-HER2.

Max move

+108.0%

High of day $4.14

Sparker timei

5:31pm ET

OSTX · Feb 13, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

OS Therapies Incorporated (OSTX) has entered into commercial manufacture agreements for its lead cancer drug, OST-HER2, targeting a rare type of bone cancer. The company has also initiated commercial-ready manufacturing processes.

The agreements and manufacturing steps are part of OS Therapies' strategy to prepare for the potential market launch of OST-HER2. The company has a free float of 27,104,500 shares and 35,214,400 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time OSTX sparks.

Download Sniper App →

Catch the next OSTX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →